Lansforsakringar Fondforvaltning AB publ Has $86.93 Million Position in Pfizer Inc. $PFE

Key Points

• Lansforsakringar Fondforvaltning AB reduced its stake in Pfizer by 1.9%, owning approximately $86.93 million worth of shares after selling 66,558 shares.
• Pfizer recently reported better-than-expected earnings, with an EPS of $0.78 and revenues of $14.65 billion, surpassing analyst estimates.
• The company's quarterly dividend of $0.43 will be paid on September 2nd, marking an annualized yield of 6.9%.

Lansforsakringar Fondforvaltning AB publ lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 1.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,430,433 shares of the biopharmaceutical company's stock after selling 66,558 shares during the period. Lansforsakringar Fondforvaltning AB publ owned about 0.06% of Pfizer worth $86,927,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. William B. Walkup & Associates Inc. grew its position in shares of Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after buying an additional 454 shares during the last quarter. Members Trust Co grew its stake in Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after purchasing an additional 467 shares during the period. Sutton Place Investors LLC grew its stake in Pfizer by 5.6% during the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after purchasing an additional 472 shares during the period. Bellevue Group AG grew its stake in Pfizer by 0.3% during the fourth quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock worth $3,756,000 after purchasing an additional 485 shares during the period. Finally, MSH Capital Advisors LLC grew its stake in Pfizer by 1.4% during the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock worth $876,000 after purchasing an additional 485 shares during the period. Institutional investors own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE opened at $25.08 on Thursday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $142.57 billion, a price-to-earnings ratio of 13.34, a PEG ratio of 0.89 and a beta of 0.52. The stock has a 50 day moving average of $24.76 and a 200 day moving average of $24.40. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer's revenue was up 10.3% on a year-over-year basis. During the same period last year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on PFE shares. Wolfe Research raised their target price on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research note on Wednesday, April 30th. HSBC cut their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a report on Monday, May 19th. The Goldman Sachs Group increased their price target on Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Berenberg Bank cut their price target on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.